Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 15;9:420. doi: 10.3389/fneur.2018.00420

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Tully, Tang, Zheng, Acosta, Tian, Hayward, Race, Mattson and Shi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Hydralazine effectively suppressed acrolein-lysine adducts in spinal cord and 3-HPMA in urine in EAE mice. In EAE plus hydralazine treatment group, hydralazine (1 mg/kg) was administered IP daily starting immediately following induction. Urine samples in both groups were collected 21–23 days post induction when the behavior deficits peak. Dotted line represent the value from age matched mice served as controls. Note the suppression of either acrolein-lysine adducts in spinal cord tissue, or 3-HPMA in urine, in EAE plus hydralazine group compared to EAE group (^*P < 0.05; ^**P < 0.01, ANOVA and post-hoc Newman-Keul's test). N = 9 in each group of acrolein measurement in tissue and 3-HPMA measurement in urine.